Michelle P. Greenman

Obstetrics and Gynecology
35 Park St
New Haven, CT 06519

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 41 publications

Preclinical in vitro and in vivo activity of trastuzumab deruxtecan against ERBB2-mutated cervical carcinomas with low HER2 expression.

Preclinical in vitro and in vivo activity of trastuzumab deruxtecan against ERBB2-mutated cervical carcinomas with low HER2 expression.

Journal: Gynecologic oncology reports
Published: June 03, 2026

Preclinical activity of tisotumab vedotin, an antibody-drug conjugate targeting tissue factor, in uterine serous carcinoma.

Preclinical activity of tisotumab vedotin, an antibody-drug conjugate targeting tissue factor, in uterine serous carcinoma.

Journal: Gynecologic oncology
Published: May 29, 2026

Integrated mutational landscape analysis of endometrial stromal sarcoma.

Integrated mutational landscape analysis of endometrial stromal sarcoma.

Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: January 27, 2026

A Phase II Evaluation of the Efficacy and Safety of Sacituzumab Govitecan in Patients with Recurrent Uterine Cancer.

A Phase II Evaluation of the Efficacy and Safety of Sacituzumab Govitecan in Patients with Recurrent Uterine Cancer.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: January 14, 2026

A Phase II Evaluation of the Efficacy and Safety of Sacituzumab Govitecan in Patients with Recurrent Uterine Cancer.

A Phase II Evaluation of the Efficacy and Safety of Sacituzumab Govitecan in Patients with Recurrent Uterine Cancer.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: January 14, 2026

Remarkable preclinical activity of trastuzumab-deruxtecan (T-DXd) in FISH-negative, HER2 IHC 1+ and 2+ expressing primary endometrial cancer cell lines and xenografts.

Remarkable preclinical activity of trastuzumab-deruxtecan (T-DXd) in FISH-negative, HER2 IHC 1+ and 2+ expressing primary endometrial cancer cell lines and xenografts.

Journal: Gynecologic oncology
Published: December 02, 2025

Long lasting response to the combination of Avutometinib and Defactinib after progression on Binimetinib in a patient with recurrent low grade serous ovarian carcinoma - A case report.

Long lasting response to the combination of Avutometinib and Defactinib after progression on Binimetinib in a patient with recurrent low grade serous ovarian carcinoma - A case report.

Journal: Gynecologic oncology reports
Published: November 19, 2025

Real World Outcomes of Pembrolizumab and Reduced-Dose Lenvatinib in Recurrent Endometrial Cancer by Platinum and p53 Status.

Real World Outcomes of Pembrolizumab and Reduced-Dose Lenvatinib in Recurrent Endometrial Cancer by Platinum and p53 Status.

Journal: Gynecologic oncology reports
Published: November 06, 2025

Oncologically safe minimally invasive management of a 25 cm cystic abdominopelvic mass using contained, controlled drainage and removal.

Oncologically safe minimally invasive management of a 25 cm cystic abdominopelvic mass using contained, controlled drainage and removal.

Journal: Gynecologic oncology reports
Published: October 17, 2025

Successful Sequential Use of the Antibody-Drug Conjugate Trastuzumab Deruxtecan After Progression on Sacituzumab Govitecan in a Recurrent Treatment-Resistant Ovarian Cancer Patient: A Case Report.

Successful Sequential Use of the Antibody-Drug Conjugate Trastuzumab Deruxtecan After Progression on Sacituzumab Govitecan in a Recurrent Treatment-Resistant Ovarian Cancer Patient: A Case Report.

Journal: Cureus
Published: October 16, 2025

HIPEC with cisplatin desensitization at the time of secondary debulking in a patient with a prior carboplatin hypersensitivity reaction.

HIPEC with cisplatin desensitization at the time of secondary debulking in a patient with a prior carboplatin hypersensitivity reaction.

Journal: Gynecologic oncology reports
Published: September 26, 2025

Immunohistochemistry, next generation sequencing (NGS), and whole exome sequencing concordance in HER2 testing in uterine serous carcinoma: a retrospective analysis.

Immunohistochemistry, next generation sequencing (NGS), and whole exome sequencing concordance in HER2 testing in uterine serous carcinoma: a retrospective analysis.

Journal: Gynecologic oncology
Published: August 23, 2025
Showing 1-12 of 41

Last Updated: 09/26/2026